Immunotherapy Coverage from Every Angle
Advertisement
Advertisement

News

AACR 2024: Immunostimulatory Properties of Low-Dose Chemotherapy in Triple-Negative Breast Cancer
AACR 2024: Response to Aromatase Inhibitors in ER-Positive Breast Cancer
NCCN Annual Conference: Update on Managing Cutaneous Melanoma
AACR 2024: Study Reports Activity With Linvoseltamab in Resistant Myeloma
AACR 2024: Biomarker Offers Clues to Melanoma Resistance to Immune Checkpoint Blockade
DLL3-Targeting T-Cell Engager Under Study in Neuroendocrine Prostate Cancer
Expanded FDA Approval for Idecabtagene Vicleucel in Relapsed or Refractory Multiple Myeloma
Anti–PD-L1 Refractory Melanoma: Combining Tyrosine Kinase and PD-1 Inhibitors
SSO 2024: Do Surgical Characteristics Impact TIL Therapy Outcomes in Melanoma?
EBCC 2024: Atezolizumab Plus Adjuvant Chemotherapy for Triple-Negative Breast Cancer
Novel T-Cell Therapy After PD-1 Blockade Under Study in Merkel Cell Carcinoma
Are Immune-Related Adverse Events Associated With Overall Survival in NSCLC?
Understanding Acquired Resistance to Immunotherapy for NSCLC: Genomic and Immunophenotypic Insights
ESMO Virtual Plenary: Neoadjuvant Tislelizumab Plus Chemotherapy and Adjuvant Tislelizumab for NSCLC
Advanced Non-Melanoma Skin Cancer: Avoiding Surgery With Upfront Systemic and Radiation Therapies
BRAF V600–Mutated Melanoma: Long-Term Outcomes With Immunotherapy
FDA Approves Bispecific Antibody Plus Chemotherapy for EGFR Exon 20 Insertion–Mutated NSCLC
Biweekly Dosing Approved by the FDA for Teclistamab-cqyv in Multiple Myeloma
CheckMate 722: Final Results With Nivolumab Plus Chemotherapy in Metastatic NSCLC
Atezolizumab Plus Chemotherapy in Advanced Urothelial Carcinoma: Final Overall Survival Analysis
Copyright © 2024 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.